Last reviewed · How we verify
JVRS-100
At a glance
| Generic name | JVRS-100 |
|---|---|
| Also known as | Cationic liposome, Plasmid DNA complex |
| Sponsor | Milton S. Hershey Medical Center |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- JVRS-100 for the Treatment of Patients With Relapsed or Refractory Leukemia (PHASE1)
- Safety, Tolerability and Immunogenicity of Fluzone® With and Without JVRS-100 in Elderly Subjects (PHASE2)
- Safety and Efficacy Study of Fluzone® Vaccine Combined With Different Doses of JVRS-100 Adjuvant (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- JVRS-100 CI brief — competitive landscape report
- JVRS-100 updates RSS · CI watch RSS
- Milton S. Hershey Medical Center portfolio CI